XML 34 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9

Collaboration Revenue - Additional Information (Details) (USD $)	3 Months Ended		0 Months Ended									1 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 05, 2012	Sep. 30, 2013	Apr. 30, 2013	Oct. 05, 2012	Mar. 29, 2013	Feb. 14, 2013	Mar. 26, 2014	Jan. 06, 2011	Dec. 18, 2013	Dec. 31, 2014	Mar. 31, 2014	Jan. 10, 2014	Jun. 28, 2013	Oct. 24, 2012
Collaboration Agreements [Line Items]
Collaboration revenue	$ 14,735,000xon_CollaborationRevenues	$ 7,837,000xon_CollaborationRevenues
Deferred revenue	111,287,000us-gaap_DeferredRevenue											113,209,000us-gaap_DeferredRevenue
Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	3,031,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember	1,882,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember
Deferred revenue	104,297,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember											107,228,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember
Oragenics ECC 1
Collaboration Agreements [Line Items]
Percent of shares outstanding at the date of achievement of future milestone			1.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Royalty rate as a percentage of net profit			25.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Required notice period for voluntary termination of collaborative agreement			90 days
Percentage of shares outstanding at the date of achievement of future milestone 2			1.50%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Percentage of shares outstanding at the date of achievement of future milestone 3			2.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Percentage of shares outstanding at the date of achievement of future milestone 4			2.50%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Percentage of shares outstanding at the date of achievement of future milestone 5			3.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Oragenics ECC 1 | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Deferred revenue	5,033,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember											5,171,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Oragenics ECC 2
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement				90 days
Consideration to be received upon achievement of future milestone 1		2,000,000xon_FutureMilestonePaymentOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember											2,000,000xon_FutureMilestonePaymentOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Consideration to be received upon achievement of future milestone 2		5,000,000xon_FutureMilestonePaymentTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember											5,000,000xon_FutureMilestonePaymentTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Consideration to be received upon achievement of future milestone 3		10,000,000xon_FutureMilestonePaymentThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember											10,000,000xon_FutureMilestonePaymentThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Royalty rate as a percentage of net sales, tier 1				10.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Oragenics ECC 2 | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Deferred revenue	4,715,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember											4,839,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Fibrocell Science, Inc.
Collaboration Agreements [Line Items]
Collaboration revenue	2,161,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember	1,310,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Required notice period for voluntary termination of collaborative agreement						90 days
Royalty rate as a percentage of net sales, tier 1						7.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Reverse stock split ratio					1-for-25
Level of net sales at which royalty rate changes to tier 2						25,000,000xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Royalty rate as a percentage of net sales, tier 2						14.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Royalty rate of savings from improvement						33.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Fibrocell Science, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	448,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember	448,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Deferred revenue	17,043,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember											17,491,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Genopaver, LLC
Collaboration Agreements [Line Items]
Collaboration revenue	669,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember	490,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember
Required notice period for voluntary termination of collaborative agreement							90 days
Genopaver, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	69,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember	69,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember
Deferred revenue	2,454,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember											2,523,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember
AquaBounty Technologies, Inc.
Collaboration Agreements [Line Items]
Royalty rate as a percentage of gross profit								16.66%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit / us-gaap_TypeOfArrangementAxis = xon_AquaBountyMember
Intrexon Energy Partners, LLC
Collaboration Agreements [Line Items]
Collaboration revenue	2,810,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember
Required notice period for voluntary termination of collaborative agreement									90 days
Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	625,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember
Deferred revenue	22,500,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember											23,125,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember
ZIOPHARM Oncology, Inc.
Collaboration Agreements [Line Items]
Collaboration revenue	3,801,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember	2,680,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Percent of shares outstanding at the date of achievement of future milestone										7.495%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Royalty rate as a percentage of net profit										50.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Required notice period for voluntary termination of collaborative agreement										90 days
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	644,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember	644,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Deferred revenue	22,549,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember											23,193,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
S & I Ophthalmic, LLC
Collaboration Agreements [Line Items]
Collaboration revenue	755,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember	879,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember
Required notice period for voluntary termination of collaborative agreement				90 days
S & I Ophthalmic, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	0xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember	0xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember
OvaXon, LLC
Collaboration Agreements [Line Items]
Collaboration revenue	644,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember	169,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember
Required notice period for voluntary termination of collaborative agreement											90 days
OvaXon, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	0xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember	0xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember
Persea Bio, LLC
Collaboration Agreements [Line Items]
Collaboration revenue	240,000xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember
Required notice period for voluntary termination of collaborative agreement												90 days
Persea Bio, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue	125,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember
Deferred revenue	4,875,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember											5,000,000us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember
Upfront | Oragenics ECC 1 | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares			4,392,425xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Collaborative arrangement consideration received, value			6,588,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember
Upfront | Oragenics ECC 2 | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares				1,348,000xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Collaborative arrangement consideration received, value				3,503,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Collaborative arrangement consideration received, value of convertible promissory note				1,956,000xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Conversion of promissory note into Common stock											698,241us-gaap_DebtConversionConvertedInstrumentSharesIssued1 / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember
Upfront | Fibrocell Science, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares						1,317,520xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Collaborative arrangement consideration received, value						7,576,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Upfront | Genopaver, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, value							3,000,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember
Upfront | Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, value									25,000,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember				25,000,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember
Upfront | ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares										3,636,926xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Collaborative arrangement consideration received, value										17,457,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Upfront | Ziopharm Oncology ECC Separate Unit of Accounting | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration revenue										1,115,000xon_CollaborationRevenues / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmOncologyEccSeparateUnitOfAccountingMember
Upfront | Ziopharm Oncology ECC Unit of Accounting One | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Deferred revenue										16,342,000us-gaap_DeferredRevenue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmOncologyEccUnitOfAccountingOneMember
Upfront | Persea Bio, LLC | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, value												5,000,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember
Supplemental Upfront | Fibrocell Science, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares														1,024,590xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember	1,243,781xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Collaborative arrangement consideration received, value														5,225,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember	7,612,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember
Milestone One | ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares																3,636,926xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_MilestoneOneMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Collaborative arrangement consideration received, value																$ 18,330,000xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_MilestoneOneMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name:	us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	xon_CollaborationAgreementsLineItems
Namespace Prefix:	xon_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Notice period required for voluntary termination of collaboration.

+ References

No definition available.

+ Details

Name:	xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix:	xon_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration agreements.

+ References

No definition available.

+ Details

Name:	xon_CollaborationRevenues
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 5.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 4.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 3.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 2.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of shares of common stock of a collaborator received by the entity as consideration

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedShares
Namespace Prefix:	xon_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Value of consideration received by the entity for collaboration

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of gross profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of net profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of cost of goods sold, as defined in the collaboration agreement, savings generated by production improvements used to calculate royalty payments to which the entity is entitled.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Value of consideration to be received from the collaborator upon achievement of milestone 1.

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentOne
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Value of consideration to be received from the collaborator upon achievement of milestone 3.

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentThree
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Value of consideration to be received from the collaborator upon achievement of milestone 2.

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentTwo
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=xon_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=xon_SupplementalUpfrontMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=xon_UpfrontMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_AquaBountyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_FibrocellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_GenopaverEccMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_OragenicsEccMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_OragenicsSecondEccMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_OvaXonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_SIOphthalmicMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: